ASCO 2020 | Reduced postoperative therapy in patients with OPC: E3311

Name: Reduced postoperative therapy in patients with OPC: E3311
Uploaded: 2020-05-28T00:00:00Z
Duration: 4 min
Description: Barbara Burtness, MD, Yale Cancer Center, New Haven, CT, USA, highlights data from the E3311 study (NCT01898494) which examined the use of reduced postoperative therapy in patients with intermediate risk p16+ oropharynx cancer (OPC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Barbara Burtness • 28 May 2020

ASCO 2020

Head and Neck Cancer

E3311

Barbara Burtness, MD, Yale Cancer Center, New Haven, CT, USA, highlights data from the E3311 study (NCT01898494) which examined the use of reduced postoperative therapy in patients with intermediate risk p16+ oropharynx cancer (OPC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).